RLAY vs TLRY · rev $3.4M vs rev $915.5M
Relay Therapeutics Inc (RLAY) versus Tilray Inc (TLRY) — a side-by-side from cached financials, not a winner call.
Relay Therapeutics Inc (RLAY) is a biotechnology company listed on NASDAQ.
Tilray Inc (TLRY) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported RLAY revenue for 2026-06-30 was $3.4M. Net income was -$157.0M. Revenue was up 11.7% from 2026-03-31 to 2026-06-30. RLAY currently screens at market cap $3.39B.
Latest reported TLRY revenue for 2026-05-31 was $915.5M. Net income was -$121.4M. Revenue was up 11.5% from 2025-05-31 to 2026-05-31. TLRY currently screens at market cap $573.9M.
RLAY currently screens at market cap $3.39B. TLRY currently screens at market cap $573.9M.
Not investment advice. Open the RLAY and TLRY stock pages for the full models.
Not investment advice.